Navigation Links
Cell Therapeutics Reports Second Quarter 2013 Financial Results
Date:7/31/2013

ent of its clinical trials; that CTI cannot predict or guarantee the outcome of preclinical and clinical studies; that CTI may not obtain reimbursement for PIXUVRI in certain markets in the E.U. as planned or at all; that the conditional marketing authorization for PIXUVRI may not be renewed or may be subject to additional conditions; that the second Phase 3 clinical trial of pacritinib will not occur as planned or at all; that CTI may not obtain favorable determinations by other regulatory, patent and administrative governmental authorities; that CTI may experience delays in the commencement of preclinical and clinical studies; risks related to the costs of developing, producing and selling PIXUVRI, pacritinib, and CTI's other product candidates; and other risks, including, without limitation, competitive factors, technological developments, costs of developing, producing and selling PIXUVRI, that CTI's operating expenses continue to exceed its net revenues, that CTI may not be able to sustain its current cost controls or further reduce its operating expenses, that CTI's average net operating burn rate may increase, that CTI will continue to need to raise capital to fund its operating expenses, but may not be able to raise sufficient amounts to fund its continued operation, as well as other risks listed or described from time to time in CTI's most recent filings with the Securities and Exchange Commission on Forms 10-K, 10-Q and 8-K.  Except as required by law, CTI does not intend to update any of the statements in this press release upon further developments.

PIXUVRI is a registered trademark of Cell Therapeutics, Inc.

Contacts:Monique Greer
+1 206.272.4343
mgreer@ctiseattle.com

Ed Bell
+1 206.282.7100
ebell@ctiseattle.com

In EuropeCTI Life Sciences Limited, Milan Branch
Laura Villa
+39 02 89659706

SOURCE Cell Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Faruqi & Faruqi, LLP Encourages Investors Who Suffered Substantial Losses Investing in Chelsea Therapeutics International, Ltd. to Contact the Firm
3. Argos Therapeutics Secures $25 million Series D Financing to Commence Phase 3 ADAPT Study in Patients with Metastatic Renal Cell Carcinoma (mRCC) in Mid-2012
4. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
5. Zacks Industry Outlook Highlights: Eli Lilly, Forest Labs, ViroPharma, Novartis and United Therapeutics
6. Oxford BioTherapeutics Appoints Senior Industry Leader to Head its New Clinical Development Operations in Basel, Switzerland
7. Nektar Therapeutics Reports Financial Results for the First Quarter of 2012
8. Cara Therapeutics Licenses Novel Kappa Opioid Agonist, CR845, to Chong Kun Dang Pharmaceutical Corporation For South Korean Market
9. Frost & Sullivan: High Uptake of New Drug Therapies and Aging Population Expansion Keep the U.S. Retinal Therapeutics Market Buoyant
10. Zenobia Therapeutics, Inc. And BioBlocks, Inc. Announce Sale Of A Joint Fragment Library Ideal For Screening By All Popular Methods
11. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS ) today reported ... the three and six months ended June 30, 2015, ... and $43.4 million for the same periods in 2014. ... the more than $90 million of revenue Isis earned ... from Bayer to license  ISIS-FXI Rx .  Isis increased ...
(Date:8/4/2015)... Pharma Ltd. (the "Company") (NASDAQ: NTEC ), a ... on its proprietary Accordion Pill platform technology, today announced ... the United States of 5,025,000 of ... of $6.00 per ordinary share, before underwriting discounts and ... by the Company.  In addition, the Company has granted ...
(Date:8/4/2015)... York , August 4, 2015 ... titled " Non-invasive Prenatal Testing (NIPT) Market (BambniTest, Harmony, ... Others) - Global Industry Analysis, Size, Volume, Share, Growth, ... According to a new market report published by Transparency ... Industry Analysis, Size, Volume, Share, Growth, Trends and Forecast ...
Breaking Medicine Technology:Isis Reports Financial Results And Highlights For Second Quarter 2015 2Isis Reports Financial Results And Highlights For Second Quarter 2015 3Isis Reports Financial Results And Highlights For Second Quarter 2015 4Isis Reports Financial Results And Highlights For Second Quarter 2015 5Isis Reports Financial Results And Highlights For Second Quarter 2015 6Isis Reports Financial Results And Highlights For Second Quarter 2015 7Isis Reports Financial Results And Highlights For Second Quarter 2015 8Isis Reports Financial Results And Highlights For Second Quarter 2015 9Isis Reports Financial Results And Highlights For Second Quarter 2015 10Isis Reports Financial Results And Highlights For Second Quarter 2015 11Isis Reports Financial Results And Highlights For Second Quarter 2015 12Isis Reports Financial Results And Highlights For Second Quarter 2015 13Isis Reports Financial Results And Highlights For Second Quarter 2015 14Isis Reports Financial Results And Highlights For Second Quarter 2015 15Isis Reports Financial Results And Highlights For Second Quarter 2015 16Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 2Intec Pharma Ltd. Announces Pricing of U.S. Initial Public Offering 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 2Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 3Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 4Non-invasive Prenatal Testing (NIPT) Market Expected to Reach USD 2.38 Billion in 2022: Transparency Market Research 5
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... ... suffering from underarm sweat. Evolutions Medical & Day Spa in Santa Barbara, CA ... only non-invasive, FDA cleared treatment that permanently eliminates sweat and odor glands in ...
(Date:8/4/2015)... ... August 04, 2015 , ... Seedstock’s 4th Annual ... 3 – 4, 2015, at UC San Diego, will explore innovations that farmers ... access, and manage resources efficiently against the dueling backdrop of a lingering Western ...
(Date:8/4/2015)... ... ... Members receiving care from a doctor who participates in a patient-centered program are ... lower -- than those members at traditional doctor practices, according to the 2014 results ... promise of patient-centered, or value-based, care to deliver better quality care at a lower ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... “Dr. Google” before calling a physician. In an effort to share more and ... care provider in Pennsylvania to publicly share patient satisfaction ratings and comments about ...
(Date:8/4/2015)... ... August 04, 2015 , ... ... full examination now offered by the world renowned Beverly Hills facelift surgeon ... appearance through cosmetic surgery techniques helps individuals to achieve an outer appearance that ...
Breaking Medicine News(10 mins):Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 2Health News:Simple, Non-Invasive, Permanent Solution To Stop Underarm Sweating in Santa Barbara 3Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 2Health News:Diversity of Urban and Hydroponic Farms of the Future to Highlight Seedstock Annual Conference Field Trip 3Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3Health News:UPMC 1st in Pa. to Share Provider Ratings 2Health News:UPMC 1st in Pa. to Share Provider Ratings 3Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 2Health News:Beverly Hills Surgeon, Dr. Paul Nassif, is Now Offering Personal Consultations with Full Examinations for Facial Plastic Surgeries 3
... , , ... Participacoes S.A.,(Bovespa: AMIL3) ("Amilpar"), in accordance with CVM (the Brazilian ... option to purchase 100% of ESHO - Empresa de Servicos ... Agreement, signed on, October 18, 2007 , in the total ...
... , , SAO PAULO , ... Sao Paulo and London involving Brazilian ethanol group,Cosan ... global,presence for Brazilian sugarcane ethanol. The assessment came from Brazilian,Sugarcane Industry ... In his view, the deal brings together two companies that ...
... New Delhi, Singapore and Washington DC (February 1, 2010) ... children with autism can learn how to teach their ... research published in the January 2010 issue of ... the Hammill Institute on Disabilities and SAGE)., Family members ...
... and then, but that experience can be horrifying for individuals ... that causes them to believe, wrongly, that they appear disfigured ... every tiny blemish looms huge rather than viewing ... researchers at UCLA have determined that the brains of people ...
... include efforts to improve food safety, expand child care ... -- The health-care portion of President Barack Obama,s 2011 ... food-safety program, $1.6 billion to expand child-care programs, and ... Kathleen Sebelius, secretary of Health and Human Services, said ...
... were more likely to delay having sex, , , MONDAY, ... education classes were more likely to delay having sex, a ... 6th- and 7th-grade students, ranging in age from 10 to ... held on Saturdays at four Philadelphia public schools that draw ...
Cached Medicine News:Health News:Amilpar Acquires ESHO 2Health News:Cosan-Shell Deal Expands Global Penetration Outlook for Brazilian Ethanol, Says Brazilian Sugarcane Industry Association 2Health News:Cosan-Shell Deal Expands Global Penetration Outlook for Brazilian Ethanol, Says Brazilian Sugarcane Industry Association 3Health News:Distance education for parents of children with autism found effective 2Health News:Why the mirror lies 2Health News:Obama Proposes $911 Billion for Health and Human Services 2Health News:Obama Proposes $911 Billion for Health and Human Services 3Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 2Health News:Abstinence-Only Classes Reduced Sexual Activity, Study Found 3
ELISA kit for the quantitative determination of autoantibodies to thyroglobulin in serum....
For the quantitative determination of Estradiol (E2) concentration in human serum or plasma....
... a direct competitive EIA for the quantitative ... plasma. A specific agent displaces Estradiol from ... binding. Estradiol then reacts successively with an ... and alkaline phosphatase labelled Estradiol . An ...
... Estradiol (E2) concentration in human serum or plasma. ... a phenolic A ring. This steroid hormone ... is the most potent natural Estrogen, produced mainly ... by the adrenal cortex, and the male testes. ...
Medicine Products: